Jpmorgan Chase & CO Vincerx Pharma, Inc. Transaction History
Jpmorgan Chase & CO
- $1.23 Trillion
- Q4 2024
A detailed history of Jpmorgan Chase & CO transactions in Vincerx Pharma, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 23 shares of VINC stock, worth $28. This represents 0.0% of its overall portfolio holdings.
Number of Shares
23
Previous 58
60.34%
Holding current value
$28
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding VINC
# of Institutions
21Shares Held
4.8MCall Options Held
0Put Options Held
0-
Sage Rhino Capital LLC1.7MShares$2.15 Million0.1% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD892KShares$1.12 Million0.01% of portfolio
-
Goldman Sachs Group Inc New York, NY631KShares$795,5600.0% of portfolio
-
Armistice Capital, LLC New York, NY567KShares$714,4330.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA286KShares$360,8280.0% of portfolio
About Vincerx Pharma, Inc.
- Ticker VINC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 21,189,800
- Market Cap $26.7M
- Description
- Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candid...